Stock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook

Stock Track11-07

Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.

The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.

The strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116940554?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-07 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116940554","market":"hk","top_or_hot":-1,"title":"Stock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook","media":"Stock Track","content":"<p>Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.</p>\n\n<p>The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.</p>\n\n<p>The strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Cytek Biosciences Soars on Stellar Q3 2024 Results, Upbeat Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-07 21:10 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTKB","symbol_name":"Cytek BioSciences","start_time":0,"source_url":"","article_id":"1116940554","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116940554","pubTimestamp":1730985023,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Cytek Biosciences  surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.The company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last yea","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTKB":"Cytek BioSciences"},"translate_title":"股票赛道Cytek Biosciences因2024年第三季度业绩出色、前景乐观而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTKB":1},"content_text":"Shares of Cytek Biosciences (NASDAQ:CTKB) surged 6.35% in pre-market trading on Wednesday, November 7, 2024, after the life sciences company reported better-than-expected financial results for the third quarter of 2024 and provided an upbeat outlook.\nThe company's revenue for the quarter rose 7.3% year-over-year to $51.5 million, beating analyst estimates by 1.6%. Notably, Cytek Biosciences turned profitable, reporting net income of $941,000, compared to a net loss of $6.46 million in the same period last year. Earnings per share (EPS) came in at $0.007, surpassing analyst expectations.\nThe strong financial performance was driven by robust demand for Cytek Biosciences' products and services. The company's management expressed confidence in its growth prospects, forecasting an average annual revenue growth rate of 12% over the next three years, outpacing the industry average of 6.4%.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116940554"}